ClinicalTrials.gg
Not yet recruitingNCT07942233HA35-PERIOCULAUpdated Nov 17, 2026

10% 35-kDa Hyaluronan Fragment (HA35) Gel for Periocular Comfort and Aesthetics

An interventional study of 10% 35-kDa hyaluronan fragment HA35 topical gel in Dry Eye Symptoms, Ocular Fatigue and Periorbital Wrinkles, sponsored by Nakhia Impex LLC. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Nakhia Impex LLC · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Asthenopia with a site in China — 2 open to participants now, 2 under way, none of them phase 3. Asthenopia · China.

Planned enrollment
10th of 14
30 · median 46
Started
2026
with 2 others
No phase
13 of 14
2 open now
Registered
14th of 14
by date
Lead sponsor
1 of 14
Nakhia Impex LLC

Among the 14 studies in Asthenopia with a site in China, this one is the 10th largest by planned enrollment, is one of 3 that started in 2026, is one of 13 with no phase, and was the 14th registered.

Asthenopia

68 studies on the registry are indexed under Asthenopia; 11 are open to participants now.

Browse Asthenopia studies →

Open to participants now

2 of the 14 studies in Asthenopia with a site in China are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 4 Asthenopia studies recruiting now, 1 sets no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Asthenopia with a site in China, or all of them as a file.
02

Study summary

To explore the efficacy and safety of 10% 35-kDa hyaluronan fragment (HA35) gel with occlusive dressing applied externally to periocular skin for improvement of ocular comfort symptoms and periocular aesthetic appearance. Participants apply gel once-daily with occlusive covering for ≥2 hours or overnight for 7 consecutive days. Assess subjective ocular discomfort, eye fatigue, conjunctival appearance, periocular wrinkle, eyelid thickness and local safety. **No gel is instilled into the eye globe.

Read the detailed description

This is a prospective, single-arm, open-label pilot clinical study. Eligible participants receive 10% 35-kDa sodium hyaluronate fragment (HA35) gel, applied as a generous even layer onto external periocular skin with eyes closed. A 10×10 cm non-woven wound dressing or steam eye-mask is placed over treatment area for occlusion to prevent drying. Each application remains in-place for ≥2 hours or overnight, once daily for 7 consecutive days. The product is for **external periocular skin use only; must NOT be instilled inside the eye**. Subjective ocular symptoms and investigator-rated periocular aesthetic signs will be evaluated at baseline, 20 minutes after first application, day-7 end-of-treatment visit. Adverse events and local tolerability are monitored throughout study. Target enrollment is 30 adult participants.

03

Conditions studied

  • Dry Eye Symptoms
  • Ocular Fatigue
  • Periorbital Wrinkles
  • Periocular Skin Condition

Browse trials for

Keywords

  • periocular aesthetics
  • eye fatigue
  • ocular discomfort
  • lateral canthal wrinkles
  • eyelid puffiness
  • hyaluronan fragment
  • HA35
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18-70 years old, male or female.
  2. Self-reported at least one of following symptoms at screening: daily ocular dryness, intermittent ocular itch, ocular fatigue, discomfort related to contact-lens wear; or desire for periocular aesthetic improvement.
  3. Able to understand study procedure, complete NRS-scale self-assessment independently.
  4. Willing to follow 7-day once-daily occlusive periocular application protocol.
  5. Voluntarily sign written informed-consent form.

Exclusion criteria

Exclusion Criteria:

  1. Active conjunctivitis, keratitis, cataract, glaucoma or other active significant ocular diseases.
  2. Pregnant or lactating women.
  3. Known / allergy to hyaluronan, sodium hyaluronate or study-gel .
  4. Scar-prone / keloid constitution.
  5. Periocular active skin wounds, dermatitis, eczema or infection at baseline.
  6. Participating in other concurrent periocular / eye-related clinical studies.
  7. Psychological or psychiatric disorder which impairs ability to comply with study requirements.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Periocular HA35 Topical Occlusive Application

    Other: 10% 35-kDa hyaluronan fragment HA35 topical gel

Interventions

  • Other10% 35-kDa hyaluronan fragment HA35 topical gel

    10% 35-kDa sodium hyaluronate gel, external periocular skin only (eyes closed, no intra-ocular instillation). Apply generous even layer; cover with occlusive dressing/steam eye-mask; leave ≥2 hours or overnight, once daily for 7 consecutive days.

06

What researchers measure

Primary outcomes

  1. Ocular Discomfort / Pain / Itch NRS Score

    0-10 numerical rating scale participant-reported score for ocular discomfort, pain or itch; 0=no discomfort, 10=maximum discomfort

    Time frame: Baseline, 20 minutes after first application, Day-7 post-7-applications

  2. Ocular Fatigue NRS Score

    Participant-reported 0-10 NRS for subjective eye fatigue; 0=no fatigue, 10=severe fatigue

    Time frame: Baseline, 20 minutes after first application, Day-7 post-7-applications

Secondary outcomes

  1. Subjective Reduced Visual Brightness NRS Score

    Participant-reported 0-10 NRS for perceived reduction of visual brightness; 0=no reduction,10=maximum reduction

    Time frame: Baseline, Day-7

  2. Ocular / Palpebral Conjunctival Appearance Composite Score

    Investigator-rated composite 0-10 score for conjunctival redness, swelling, congestion; 0=normal appearance; 10=severe redness/swelling/congestion.

    Time frame: Baseline, Day-7

  3. Lateral Canthal Wrinkle Severity NRS Score

    Investigator visual rating 0-10 for lateral canthal wrinkle severity; 0=no wrinkle; 10=maximum wrinkle severity

    Time frame: Baseline, Day-7

  4. Upper-Eyelid Thickness / Puffiness NRS Score

    Investigator visual-tactile rating 0-10 for upper-eyelid thickness and puffiness; 0=no puffiness/thickening;10=severe puffiness

    Time frame: Baseline, Day-7

  5. Palpebral Fissure Enlargement Change Score

    Investigator-rated change-from-baseline score; 0=no change; higher value indicates greater improvement of palpebral fissure opening appearance

    Time frame: Baseline, Day-7

  6. Periocular Tissue-Softening Change Score

    Investigator visual-palpation change-from-baseline score;0=no change; higher value indicates greater softening/relaxation of periocular tissue

    Time frame: Baseline, Day-7

  7. Participant Overall Satisfaction Questionnaire Score

    Participant 0-10 satisfaction score for overall periocular and ocular-comfort improvement;0=most dissatisfied, 10=most satisfied

    Time frame: Day-7 end-of-treatment visit

  8. Adverse Event Incidence

    Incidence of product-related local or ocular adverse reactions, including stinging, redness, irritation, itching, eye irritation

    Time frame: Throughout 7-day study period

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jan 2027, 1 month later.

Of 38 interventional studies with no phase under Asthenopia, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's planned 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jan 7, 2027
CompletionEst.
Jan 14, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942233
Lead sponsor
Nakhia Impex LLC
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jan 7, 2027 (estimated)
Completion
Jan 14, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Mizhou Hui, Dr
Contact
mizhou.hui@alumni.utoronto.ca
13484005199

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion